2026-526215-10-00RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, and Activity of a Novel Oral Anticancer Drug (FLC‑436) in Patients With Refractory or Relapsed Solid Malignancies
Fileclo Sp. z o.o.1 site in 1 country30 target enrollmentStarted: August 17, 2026Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Clinical trial information point
Scientific
Fileclo Sp. z o.o.
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389Obesity / Right heart failure (healthy participants)2024-514853-31-00Corteria Pharmaceuticals80
Completed
Phase 1
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zosurabalpin following Intravenous Administration in Healthy ParticipantsThere is no medical condition being investigated. This is a safety and pharmacokinetic study to be performed in healthy participants.2023-505411-20-00F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG30
Recruiting
Phase 1
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.Malaria2024-516911-26-00Novartis Pharma AG94
Completed
Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s DiseaseEarly Idiopathic Parkinson’s Disease (PD)2023-504412-14-00F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG20
Recruiting
Phase 1
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesB-cell non-Hodgkin lymphoma (NHL)2024-514938-20-00Regeneron Pharmaceuticals Inc.65